| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5658251 | Gastroenterology | 2017 | 30 Pages |
Abstract
In an analysis of data from a pilot FIT-based biennial screening program, we found that among persons screened by FIT, 23% developed FIT interval cancer. FIT therefore detects CRC with 77% sensitivity. The proportion of FIT interval cancers in FIT screening appears to be lower than that with guaiac fecal occult blood testing. Clinical trial registry: yes, www.trialregister.nl, trial number: NTR5385.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Manon van der Vlugt, Esmée J. Grobbee, Patrick M.M. Bossuyt, Amanda Bos, Evelien Bongers, Wolfert Spijker, Ernst J. Kuipers, Iris Lansdorp-Vogelaar, Manon C.W. Spaander, Evelien Dekker,